Comparison Between Multi-omics Models Including DNA Methylation in CfDNA, Quantitative Determination of Epstein-Barr Virus Nucleic Acid and Serological Double Antibody Detection in Early Screening of Nasopharyngeal Carcinoma

What this Trial Is About

Researchers are evaluating early screening methods for nasopharyngeal carcinoma (NPC), a cancer with distinct characteristics in Chinese populations. This study compares the performance of multi-omics models, including DNA methylation and fragmentome analysis, with routine clinical tests such as Epstein-Barr virus (EBV) DNA quantification and serological double antibody tests. The goal is to improve detection accuracy, reduce false positives and negatives, and increase early-stage NPC diagnosis rates. The study includes two groups: participants newly diagnosed with NPC and participants without a cancer diagnosis after routine screening. It assesses multi-omics models like circulating cell-free DNA (cfDNA) methylation alongside EBV DNA and antibody tests over a two-year period. These tests are evaluated for sensitivity, specificity, and predictive values in detecting NPC and early-stage disease. Participants aged 40 to 74 will provide consent and undergo screening tests without receiving treatment interventions. Researchers will monitor false positive and negative rates, sensitivity, specificity, and predictive values of the tests. The study involves observing outcomes for two years to assess early detection accuracy while participants continue their usual care. The trial is sponsored by the First Affiliated Hospital, Sun Yat-Sen University.

Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection